GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (MIL:DIA) » Definitions » COGS-to-Revenue

Diasorin SpA (MIL:DIA) COGS-to-Revenue : 0.35 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA COGS-to-Revenue?

Diasorin SpA's Cost of Goods Sold for the three months ended in Dec. 2023 was €107 Mil. Its Revenue for the three months ended in Dec. 2023 was €302 Mil.

Diasorin SpA's COGS to Revenue for the three months ended in Dec. 2023 was 0.35.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Diasorin SpA's Gross Margin % for the three months ended in Dec. 2023 was 64.59%.


Diasorin SpA COGS-to-Revenue Historical Data

The historical data trend for Diasorin SpA's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA COGS-to-Revenue Chart

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.32 0.33 0.34 0.35

Diasorin SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.34 0.35 0.38 0.35

Diasorin SpA COGS-to-Revenue Calculation

Diasorin SpA's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=407.024 / 1148.21
=0.35

Diasorin SpA's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=107.024 / 302.21
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diasorin SpA  (MIL:DIA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Diasorin SpA's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 107.024 / 302.21
=64.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Diasorin SpA COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA (MIL:DIA) Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin SpA is a biotechnology company engaged in developing, producing, and marketing reagent kits for laboratory diagnostics around the world. The business has focused on the immunodiagnostic market, molecular diagnostics, and Life Science sector. The company has a presence in Italy, Europe, North America, and the Rest of the world, where the majority of its revenue is from North America followed by Italy.

Diasorin SpA (MIL:DIA) Headlines

From GuruFocus